Trial Outcomes & Findings for Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations (NCT NCT02795156)

Last Updated: 2023-12-05

Results Overview

ORR is defined as the percentage of patients with confirmed complete response (CR) or confirmed partial response (PR), i.e., two CRs and/or PRs at least 4 weeks apart, according to the RECIST v1.1 criteria. CR=disappearance of all target and non-target lesions. PR=at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

100 participants

Primary outcome timeframe

every 8 weeks until tumor progression or treatment discontinuation, up to 45 months.

Results posted on

2023-12-05

Participant Flow

Participant milestones

Participant milestones
Measure	Arm 1 Patients with non-small cell lung cancer who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. afatinib: 40 mg orally once daily for each 28-day cycle regorafenib: 160 mg orally once daily for the first 21-days of each 28-day Cabozantinib: 60 mg orally once daily for each 28-day cycle	Arm 2 Patients with urothelial carcinoma who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. Afatinib: 40 mg orally once daily for each 28-day cycle Regorafenib: 160 mg orally once daily for the first 21-days of each 28-day Cabozantinib: 60 mg orally once daily for each 28-day cycle	Arm 3 Patients with non-colon gastrointestinal cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. Afatinib: 40 mg orally once daily for each 28-day cycle Regorafenib: 160 mg orally once daily for the first 21-days of each 28-day Cabozantinib: 60 mg orally once daily for each 28-day cycle	Arm 4 Patients with upper aerodigestive tract cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. afatinib: 40 mg orally once daily for each 28-day cycle regorafenib: 160 mg orally once daily for the first 21-days of each 28-day Cabozantinib: 60 mg orally once daily for each 28-day cycle
Overall Study STARTED	39	10	42	9
Overall Study COMPLETED	0	0	0	0
Overall Study NOT COMPLETED	39	10	42	9

Reasons for withdrawal

Reasons for withdrawal
Measure	Arm 1 Patients with non-small cell lung cancer who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. afatinib: 40 mg orally once daily for each 28-day cycle regorafenib: 160 mg orally once daily for the first 21-days of each 28-day Cabozantinib: 60 mg orally once daily for each 28-day cycle	Arm 2 Patients with urothelial carcinoma who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. Afatinib: 40 mg orally once daily for each 28-day cycle Regorafenib: 160 mg orally once daily for the first 21-days of each 28-day Cabozantinib: 60 mg orally once daily for each 28-day cycle	Arm 3 Patients with non-colon gastrointestinal cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. Afatinib: 40 mg orally once daily for each 28-day cycle Regorafenib: 160 mg orally once daily for the first 21-days of each 28-day Cabozantinib: 60 mg orally once daily for each 28-day cycle	Arm 4 Patients with upper aerodigestive tract cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. afatinib: 40 mg orally once daily for each 28-day cycle regorafenib: 160 mg orally once daily for the first 21-days of each 28-day Cabozantinib: 60 mg orally once daily for each 28-day cycle
Overall Study Progressive Disease	22	7	34	7
Overall Study Adverse Event	13	2	3	2
Overall Study Death	1	1	1	0
Overall Study Physician Decision	1	0	1	0
Overall Study Withdrawal by Subject	2	0	3	0

Baseline Characteristics

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Arm 1 n=39 Participants Patients with non-small cell lung cancer who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. afatinib: 40 mg orally (p.o.) once daily for each 28-day cycle regorafenib: 160 mg p.o. once daily for the first 21-days of each 28-day Cabozantinib: 60 mg p.o. once daily for each 28-day cycle	Arm 2 n=10 Participants Patients with urothelial carcinoma who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. afatinib: 40 mg orally (p.o.) once daily for each 28-day cycle regorafenib: 160 mg p.o. once daily for the first 21-days of each 28-day Cabozantinib: 60 mg p.o. once daily for each 28-day cycle	Arm 3 n=42 Participants Patients with non-colon gastrointestinal cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. afatinib: 40 mg orally (p.o.) once daily for each 28-day cycle regorafenib: 160 mg p.o. once daily for the first 21-days of each 28-day Cabozantinib: 60 mg p.o. once daily for each 28-day cycle	Arm 4 n=9 Participants Patients with upper aerodigestive tract cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. afatinib: 40 mg orally (p.o.) once daily for each 28-day cycle regorafenib: 160 mg p.o. once daily for the first 21-days of each 28-day Cabozantinib: 60 mg p.o. once daily for each 28-day cycle	Total n=100 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants
Age, Categorical Between 18 and 65 years	9 Participants n=93 Participants	2 Participants n=4 Participants	12 Participants n=27 Participants	5 Participants n=483 Participants	28 Participants n=36 Participants
Age, Categorical >=65 years	30 Participants n=93 Participants	8 Participants n=4 Participants	30 Participants n=27 Participants	4 Participants n=483 Participants	72 Participants n=36 Participants
Sex: Female, Male Female	25 Participants n=93 Participants	3 Participants n=4 Participants	13 Participants n=27 Participants	1 Participants n=483 Participants	42 Participants n=36 Participants
Sex: Female, Male Male	14 Participants n=93 Participants	7 Participants n=4 Participants	29 Participants n=27 Participants	8 Participants n=483 Participants	58 Participants n=36 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants
Race (NIH/OMB) Asian	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants
Race (NIH/OMB) Black or African American	2 Participants n=93 Participants	0 Participants n=4 Participants	3 Participants n=27 Participants	0 Participants n=483 Participants	5 Participants n=36 Participants
Race (NIH/OMB) White	35 Participants n=93 Participants	10 Participants n=4 Participants	39 Participants n=27 Participants	9 Participants n=483 Participants	93 Participants n=36 Participants
Race (NIH/OMB) More than one race	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants
Race (NIH/OMB) Unknown or Not Reported	2 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	2 Participants n=36 Participants
Region of Enrollment United States	39 Participants n=93 Participants	10 Participants n=4 Participants	42 Participants n=27 Participants	9 Participants n=483 Participants	100 Participants n=36 Participants

PRIMARY outcome

Timeframe: every 8 weeks until tumor progression or treatment discontinuation, up to 45 months.

Population: All enrolled patients are included.

Outcome measures

Outcome measures
Measure	Arm 1 n=39 Participants Patients with non-small cell lung cancer who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. Afatinib: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Regorafenib: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Cabozantinib: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.	Arm 2 n=10 Participants Patients with urothelial carcinoma who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. Afatinib: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Regorafenib: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Cabozantinib: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.	Arm 3 n=42 Participants Patients with non-colon gastrointestinal cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. Afatinib: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Regorafenib: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Cabozantinib: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.	Arm 4 n=9 Participants Patients with upper aerodigestive tract cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. Afatinib: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Regorafenib: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Cabozantinib: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations	10.3 percentage of participants Interval 2.87 to 24.22	0 percentage of participants No participants in this arm met the definition of Overall Response Rate. Confidence interval can't be calculated.	7.1 percentage of participants Interval 1.5 to 19.48	0 percentage of participants No participants in this arm met the definition of Overall Response Rate. Confidence interval can't be calculated.

SECONDARY outcome

Timeframe: Every 8 weeks until tumor progression or treatment discontinuation, up to 45 months

Population: All enrolled participants are included.

Clinical Benefit Rate (CBR) is defined as the percentage of patients with confirmed complete response (CR) or confirmed partial response (PR) or stable disease (SD) ≥ 6 months according to RECIST v1.1. Confirmed response is defined as two CRs and/or PRs at least 4 weeks apart, according to the RECIST v1.1 criteria. CR=disappearance of all target lesions. PR=at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Stable Disease= Neither sufficient shrinkage to qualify for PR nor sufficient increase of 20% in the sum of diameters or presence of a new lesion to qualify for progressive disease (PD), taking as reference the smallest (nadir) sum of diameters since the treatment started.

Outcome measures

Outcome measures
Measure	Arm 1 n=39 Participants Patients with non-small cell lung cancer who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. Afatinib: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Regorafenib: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Cabozantinib: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.	Arm 2 n=10 Participants Patients with urothelial carcinoma who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. Afatinib: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Regorafenib: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Cabozantinib: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.	Arm 3 n=42 Participants Patients with non-colon gastrointestinal cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. Afatinib: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Regorafenib: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Cabozantinib: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.	Arm 4 n=9 Participants Patients with upper aerodigestive tract cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. Afatinib: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Regorafenib: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Cabozantinib: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
Clinical Benefit Rate in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations	15.4 percentage of participants Interval 5.86 to 30.5	0 percentage of participants No participants met the definition of Clinical Benefit Rate. There is no confidence interval to be calculated.	21.4 percentage of participants Interval 10.3 to 36.8	11.1 percentage of participants Interval 0.28 to 48.2

SECONDARY outcome

Timeframe: Every 8 weeks until tumor progression or treatment discontinuation, up to 45 months

Population: All enrolled participants were included.

Time to treatment failure is measured from the first day of treatment until the patient is removed from study for toxicity, disease progression per RECIST v1.1, patient choice, or death. Progressive disease (PD) per RECIST v1.1 is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest (nadir) sum since the treatment started, or the appearance of one or more new lesions. Requires not only 20% increase, but absolute increase of a minimum of 5 mm over the sum.

Outcome measures

Outcome measures
Measure	Arm 1 n=39 Participants Patients with non-small cell lung cancer who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. Afatinib: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Regorafenib: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Cabozantinib: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.	Arm 2 n=10 Participants Patients with urothelial carcinoma who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. Afatinib: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Regorafenib: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Cabozantinib: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.	Arm 3 n=42 Participants Patients with non-colon gastrointestinal cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. Afatinib: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Regorafenib: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Cabozantinib: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.	Arm 4 n=9 Participants Patients with upper aerodigestive tract cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. Afatinib: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Regorafenib: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Cabozantinib: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
Time to Treatment Failure (TTF) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations	2.1 months Interval 1.6 to 2.8	1.8 months Interval 1.1 to 1.9	1.9 months Interval 1.8 to 3.5	2.0 months Interval 1.0 to 4.3

SECONDARY outcome

Timeframe: Every 8 weeks until tumor progression or treatment discontinuation, up to 45 months

Population: All enrolled participants were included.

Progression Free Survival (PFS) is defined as the time from the first day of study drug administration (Day 1) to disease progression as defined by the RECIST v1.1, or death on study. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. Progressive disease (PD) per RECIST v1.1 is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest (nadir) sum since the treatment started, or the appearance of one or more new lesions. Requires not only 20% increase, but absolute increase of a minimum of 5 mm over the sum.

Outcome measures

Outcome measures
Measure	Arm 1 n=39 Participants Patients with non-small cell lung cancer who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. Afatinib: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Regorafenib: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Cabozantinib: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.	Arm 2 n=10 Participants Patients with urothelial carcinoma who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. Afatinib: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Regorafenib: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Cabozantinib: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.	Arm 3 n=42 Participants Patients with non-colon gastrointestinal cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. Afatinib: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Regorafenib: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Cabozantinib: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.	Arm 4 n=9 Participants Patients with upper aerodigestive tract cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations. Afatinib: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Regorafenib: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months. Cabozantinib: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
Progression-Free Survival in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations	3.2 months Interval 2.7 to 4.4	1.9 months Interval 1.5 to 3.3	3.1 months Interval 2.3 to 4.2	2.8 months Interval 1.8 to 8.6

Adverse Events

Arm 1

Serious events: 16 serious events

Other events: 39 other events

Deaths: 14 deaths

Arm 2

Serious events: 6 serious events

Other events: 10 other events

Deaths: 1 deaths

Arm 3

Serious events: 14 serious events

Other events: 41 other events

Deaths: 13 deaths

Arm 4

Serious events: 5 serious events

Other events: 8 other events

Deaths: 3 deaths

Serious adverse events

Other adverse events

Additional Information

Sarah Cannon Development Innovations, LLC

Phone: 844-710-6157

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Restriction type: LTE60